John Beadle

And so right now we're investing around five core investment theses.

So the first, which is where ascertain falls, is automating workflows.

The second is reimagining the consumer experience.

There we've built two companies.

One is called Hume AI, which is a voice AI company that is able to drive a lot of automation for customer service applications.

In particular, it's able to really deeply understand emotion and drive better empathy for those types of applications.

Another company called Caregentic, which is using AI agents to help with

care journey automation and so navigating patients a lot more effectively across the health system and creating a digital front door to be able to extend the effectiveness of their care team into their homes with them wherever they go to make it a lot easier to be able to access

access the health system without needing to spend hours on the phone or needing to go between lots of different sets of providers.

Third one is creating and amplifying new biomarkers.

And so that's one that we're really leaning into.

And that leverages, as I mentioned earlier, this thesis we have around finding great teams of investigators that are developing world-class science and scientific breakthroughs that we can build around.

There we built a company called Optane, which is in the retinal imaging space.

So there we've developed hardware plus software to be able to detect a lot of different diseases at the point of care using a 30 second eye scan.

And so you'll take a 30 second retinal scan that will be able to run using this proprietary hardware that we've developed.

And then we can detect diabetic retinopathy, AMD, glaucoma, cardiovascular disease, neurological conditions.

and then create a referral from primary care into the service lines to be able to get downstream care to patients that otherwise might not be screened for those types of eye and systemic diseases.

And then the last one is around unlocking rural evidence to accelerate clinical trials.

And so how do we partner with health systems and the life sciences community to be able to access patients for trials, data sets, all sorts of resources that are scarce that can enable

pharma to be able to get patients life-saving therapies a lot more faster, a lot more quickly and more effectively.